Novartis won US approval for its $2 million gene therapy
25 May 2019
Swiss drugmaker Novartis on won US approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. The Food and Drug Administration approved Zolgensma for children